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Abstract:  A new tetramic acid glycoside, aurantoside K, was isolated from a marine 
sponge belonging to the genus Melophlus. The structure of the compound was elucidated 
on the basis of spectroscopic analysis (
1H NMR, 
1H–
1H COSY, HSQC, and HMBC, as 
well as high-resolution ESILCMS). Aurantoside K did not show any significant activity in 
antimalarial, antibacterial, or HCT-116 cytotoxicity assays, but exhibited a wide spectrum 
of antifungal activity against wild type Candida albicans,  amphotericin-resistant  
C. albicans,  Cryptococcus neoformans,  Aspergillus niger,  Penicillium  sp.,  Rhizopus 
sporangia and Sordaria sp.  
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1. Introduction  
Sponges (Porifera) are multicellular organisms that remain the most important source in the field of 
marine drug discovery. Sponges are a well-known source of new/novel bioactive natural products of 
pharmaceutical and medical relevance [1–7]. Marine sponges belonging to the genus Melophlus 
(Astrophorida, Ancorinidae) are promising sources of structurally unusual and diverse secondary 
metabolites.  Meophlus spp. sponges have been reported to produce compounds primarily from   
three classes, specifically tetramic acid derivatives [8–10], saponin derivatives [11,12], and 
depsipeptides [13] with potent and varied biological activities. The melophlins [8–10] are tetramic 
acids with long-chain saturated alkane side chains and differ significantly from the aurantosides, 
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another sponge-produced class of tetramic acids containing chlorinated polyene side chains and 
displaying di- and tri-saccharide substituents attached to nitrogen. Aurantosides have been reported to 
display antifungal and cytotoxic activities and have been isolated from sponges of the family 
Theonellidae [14–18] but to date have not been reported from Melophlus. As part of our continuing 
search for new bioactive metabolites from Fijian invertebrates, we investigated an extract from 
Melophlus sp. exhibiting significant antifungal activity. We report here the isolation, structure 
elucidation, and biological activity of a novel compound aurantoside K (1) resulting from these studies. 
2. Results and Discussion  
The crude MeOH extract was separated by solvent partitioning between 90% MeOH(aq) and hexane. 
The MeOH fraction was concentrated under vacuum and fractionated by flash chromatography on 
ODS-A to afford ten fractions, of which three were toxic to both wild type C. albicans and 
amphotericin-resistant C. albicans, at 250 µg/disc. The +HRESILCMS profile for the active fractions 
displayed mass spectral isotopic patterens suggestive of the presence of one or two chlorine atoms for 
each of the three major compounds. The mass spectral data were used to search the MarinLit database 
(2011, vpc 15.5) [19], allowing the identification of aurantosides I [17] (2) and A [14] (3) for two of 
the three active compounds. Compound 1 contained one chlorine atom and did not match any of the 
candidate formulas from MarinLit. Among the aurantosides (1–3) detected in this study (Chart 1), 
compound  1 showed unknown molecular mass and was subjected to further purification by   
reversed-phase HPLC to afford the new tetramic acid glycoside aurantoside K (1). The compound was 
isolated as a bright orange amorphous solid.  
The +HRESILCMS analysis of aurantoside K (1) supported a molecular formula of C33H44ClN2O15 
(m/z 743.2428 [M + H]
+); calcd. for C33H44ClN2O15, 743.2425; ∆ = 0.4 ppm, (−ESILCMS m/z 741.43  
[M − H]
−), which was consistent with the NMR data. The 
1H NMR spectra (Table 1) of compound 1 
was nearly superimposable on aurantoside I [17], except for the absence of the C-2"' methoxy group on 
the sugar unit, which is replaced by a hydroxyl group by interpretation of 1D and 2D NMR spectra 
(Figure 1). This was also confirmed by the ESILCMS fragmentation patterns of 1 and 2. The 
+HRESILCMS disclosed that compound 1 was 14 amu (CH2 unit) lighter than aurantoside I (2) further 
affirming the replacement of a methoxy group with a hydroxyl group. Interpretation of the COSY 
spectrum revealed that 1 had a polyene chain from C-8 to C-16 with E configurations. Two   
carbonyl-attached methylene (H-5a and H-5b, 2.54 and 2.59 ppm) were observed in DMSO-d6 which 
showed HSQC correlations to C-5 at 36.3 ppm indicating that the aliphatic methylene protons are 
attached to C-5. These protons (H-5) also showed HMBC correlations to a quaternary carbonyl carbon 
and the amide carbonyl carbon suggesting that C-3, C-4, C-5 and C-6 are part of the tetramic acid 
moiety or attached to it. The COSY correlations of proton H-4 and the aliphatic methylene H-5 also 
indicate the same tetramic acid core found in aurantoside I (2). The chlorine atom was placed on C-17 
based on its 
13C chemical shift (δC 133.0 ppm) and the splitting pattern of the neighboring proton H-16 
(δH 6.44 ppm, d, J = 10.2 Hz) and H3-18 (δH 2.22 ppm, s) (Figure 1).  
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Chart 1. Compound 1 and the known aurantosides A and I. 
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Figure 1. The key 
1H–
1H COSY and HMBC correlations of compound 1. 
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Table 1. NMR Spectroscopic Data (500/125 MHz, DMSO-d6) for Aurantoside K (1). 
Position  δH (J in Hz)  δC 
a COSY  HMBC 
b 
1 - c    
2 - c    
3 -  170.3     
4 4.16  br  63.8  5a,  5b   
5a  2.54, m  36.3  4  3, 6 
5b  2.59, m    4  3, 6 
6 -  170.3     
7 - c    
8  6.97 br, d (18.3)  143.6  9   
9  6.61, dd (10.4, 16.9)  130.6  8, 10   
10  6.38, dd (11.3, 13.2)  127.5  9, 11   
11  7.97, dd (13.6, 13.8)  138.4  10, 12   
12  7.12, dd (12.4, 13.1)  120.2  11, 13   
13  7.55, dd (15.1, 11.1)  144.2  12, 14   
14  6.71, d (11.8)  130.9  12, 13, 15   
15 6.58–6.48,  m  133.4  14   
16  6.44, d (10.2)  125.6  18  18 
17 -  133.0     
18  2.22, s  26.0  16  16, 17 
1' 5.21,  m  79.0     
2' 4.37  br  79.5     
3' 4.36  br  83.8     
4' 3.53,  m  63.66     
5a'  3.27, d (8.8)  77.3    2' 
5b'  3.39, dd (12.3, 6.6)      2' 
1" 4.79,  s  102.3     
2" 3.59,  m  68.4  4"   
3" 3.50,  m  68.9  4"   
4"  3.18, d (11.6)  63.67  2", 3"  1", 3" 
5"  4.24, d (11.6)  74.1     
1"' 4.93,  m  102.5     
2"'  3.08, t (10.9)  67.57  3"'   
3"'  3.71, dd (11.2, 5.5)  67.60  2"', 4"'  4"' 
4"' 3.38,  m  68.5  3"'   
5"' 1.22 
d  c    
a obtained from 2D NMR; 
b HMBC correlations are from proton(s) stated to the indicated carbon;  
c Not observed; 
d obtained from COSY spectrum. 
The reported mass spectrum of aurantoside I [17] displayed a pseudomolecular ion at m/z 757  
([M + H]
+) and a fragment at m/z 627 corresponding to loss of 130 Da that was assigned to loss of  
5-deoxy-2-O-methylarabinofuranose. Compound 1 ( m/z  = 743 [M + H]
+) also showed a distinct 
fragment ion at m/z 627 however, the difference was 116 daltons, further indicating that the sugar unit 
which is cleaved off is indeed 14 amu smaller than the sugar III of aurantoside I (2). Moreover, the 
psuedomolecular ion of compound 1 at m/z 743 produced prominent fragment ions at m/z 627   Mar. Drugs 2012, 10                 
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[M + H − sugar III]
+, 495 [M + H − sugar II + III]
+ and at 363 [M + H − sugar I + sugar II + III]
+, 
which were generated due to the cleavage of the three glycosidic bonds, confirming the trisaccharide 
series. Although the 
1H NMR signals were complicated by broad and overlapping signals, two distinct 
anomeric protons were identified from the 
1H–
1H COSY spectrum (Figure 1). The high field signal  
(δH 4.79 ppm) was assigned to H-1" of the arabinopyranose structure (sugar II) while the other 
anomeric proton H-1"', (δH 4.93 ppm) was assigned to the 2"'-des-O-methyl derivative of   
5-deoxypentofuranose unit (sugar III) with the signal at δH 1.22 ppm due to the methyl group of sugar III. 
Absence of an O-methyl signal in the NMR spectra and an upfield shift of C-2"' (δC 67.6 ppm) were 
consistent with replacement of the 2"' OMe group by a hydroxyl group when compared to the known 
aurantosides [14,17]. The remainder of the structure of 1 was confirmed by comparison of the 1D and 
2D NMR data against those reported for the other known aurantosides, confirming the flat structure of 
1 as a new congener designated as aurantoside K.  
The biosynthetic relationship between aurantoic acid and aurantosides has not been established to 
date. However, according to the literature [14–17,20], the marine-derived tetramic acid glycosides 
aurantosides A–F and rubrosides A–H are all derived from L-aspartic acid and carry D-saccharides 
which may well be indicative of a common biosynthetic pathway to these polyene tetramic acid 
metabolites. Furthermore, aurantosides are homogeneous in terms of the polyene chain, however the 
sugar moiety especially trisaccharides plays an important role for the biological activity. 
The biological activities of the purified compound 1  was examined in cytotoxicity [21],   
antimalarial [22–24], antibacterial [25] and antifungal [9,25] bioassays. Aurantoside K (1) failed to 
show any significant activity against HCT-116 human cancer cell lines  and it did not exhibit 
antibacterial activity against methicillin-resistant Staphylococcus aureus or vancomycin-resistant 
Enterococcus faecium. No antimalarial activity against Plasmodium falciparum parasites was shown 
by compound 1. However, 1 displayed appreciable antifungal activity against amphotericin-resistant  
C. albicans and  wild type C. albicans with the minimum inhibitory concentration (MIC) at   
31.25 μg/mL and 1.95 μg/mL, respectively. Furthermore, 1 displayed potent inhibitory activity against 
the pathogenic yeast Cryptococcus neoformans with a clear inhibition zone of 14 mm diameter at the 
concentration of 100 μg/disc. Additionally, 1 significantly inhibit the pathogenic fungi A. niger (28 mm), 
Penicillium sp. (31 mm), R. sporangia (21 mm) and Sordaria sp. (29 mm) at a test concentration of 
100 μg/disc.  
3. Experimental Section  
3.1. General Experimental Procedure 
Optical rotation was measured on a Rudolph automatic polarimeter. UV spectrum was acquired in 
spectroscopy grade methanol using a PerkinElmer Lambda 35 spectrophotometer. NMR spectra (1D and 
2D NMR; COSY, HSQC, and HMBC) were acquired on a UXNMR, Bruker Analytische Messtechnik 
GmbH NMR spectrometer using a 5 mm broadband probe, and were referenced to the residual solvent 
(δH 2.50 ppm and δC 39.5 ppm for DMSO-d6) operating at 500/125 MHz. Electrospray ionization mass 
spectra (ESIMS) were acquired using an Agilent 1100 Series separations module equipped with an 
Agilent 1100 Series LC/MSD mass detector in both positive and negative ion modes. Purification was Mar. Drugs 2012, 10                 
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done on a Zorbax ODS 5 µm 4.6 × 250 mm column. Analytical and semi-preparative HPLC was 
performed using a Waters 515 pump connected to a 2487 UV-Vis detector. TLC analyses were carried 
out using glass plate pre-coated silica gel 60 RP-18 F254S (Merck, Darmstadt, Germany). Analytical 
grade solvents were utilized for chromatographic analysis. Burdick and Jackson high purity solvents 
were used for HPLC while Riedel-de Haen, Chromasolv LCMS grade solvents were used for LCMS. 
3.2. Biological Material 
The sponge Melophlus sp. was collected by hand using SCUBA at a depth of 10 m from Cicia, Lau 
group, Fiji Islands (17°47'33''S, 179°23'94''W) in September 2008 during a three week biodiversity 
expedition in the Central Lau group. The sponge (brownish maroon external color and dark green 
internal color) was soft to touch and consisted of a few 5–9 mm diameter oscules. This sponge 
produced a bright orange secretion which would stain any surface it came into contact with, suggesting 
the presence of interesting chemistry. The sponge was identified by Prof. John Hooper, Queensland 
Museum, Australia. A voucher specimen (G-0634) has been preserved at the Marine Reference 
Collection, The University of the South Pacific, Fiji Islands and at Georgia Institute of Technology, USA.  
3.3. Extraction and Isolation 
The frozen sponge (1220 g wet weight) was extracted with MeOH at room temperature, yielding  
15 g of crude extract after solvent removal in vacuo. A portion of the crude extract (6.5 g) was 
partitioned between 90% MeOH(aq) and hexane. The MeOH extract was purified by flash 
chromatography on ODS-A (6 nm S–150 µm) using a stepwise gradient solvent system of H2O-MeOH 
to afford ten fractions (F1–F10). Fractions F7–F9 (eluted with 70% to 90% MeOH(aq)) were pooled due 
to their significant anti-Candida activity. These fractions contained chlorinated compounds as 
illustrated by +HRESILCMS. The combined fraction (F7–F9) was further purified by semi-preparative 
RP-HPLC (Zorbax ODS 5 µm 4.6 × 250 mm column) with 45% CH3CN(aq) and 0.1% TFA followed 
by 40% CH3CN(aq) and 0.1% TFA at a flow rate of 3 mL/min and was detected at 254 nm to furnish 
pure aurantoside K (1, 5 mg). 
Aurantoside K (1): orange solid, [α]
27
D −127° (c 0.2, MeOH): UV (MeOH) λmax (log ε) 434 (3.95), 
265 (2.41) nm; NMR data, see Table 1; HRESIMS m/z 743.2428 [M + H]
+ (calcd. for C33H44ClN2O15, 
743.2425). 
3.4. Agar Diffusion Assay 
Susceptibility discs (6 mm in diameter) were impregnated with 100 µg of the pure compound 
dissolved in MeOH and placed on potato dextrose agar (PDA) plates inoculated with the test fungal 
pathogens A. niger, Penicillium sp., R. sporangia and Sordaria sp. The plates were observed for zones 
of inhibition after 7–10 days of incubation at room temperature. The compound was also assayed 
against  Cr. neoformans ATCC 32045 which was inoculated on PDA agar plates, and zones of 
inhibition were recorded after 24 h of incubation at 27 °C. In all cases, for the controls containing only 
the respective amount of solvent, no growth inhibition was observed. The procedure was the same as 
previously reported [9]. Mar. Drugs 2012, 10                 
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3.5. Proliferation Assay 
Antimalarial activity was determined with a SYBR Green based parasite proliferation assay, 
adapted from Smilkstein [22] and Bennett [23]. Briefly, P. falciparum parasites (3D7 strain 
MR4/ATCC, Manassas, VA) were cultured in human O+ erythrocytes as previously described [24]. 
Compound  1 was diluted in complete medium and 40 µL transferred to 96-well assay plates.   
To this 80 µL of complete media with 3D7 infected erythrocytes were dispensed in order to obtain a 
2.5% hematocrit and 0.5% parasitemia in the assay. Uninfected erythrocytes were dispensed into the 
background wells at the same final hematocrit. Plates were incubated for 72 h in a low oxygen 
environment (96% N2, 3% CO2, 1% O2) in a modular incubation chamber. The plates were sealed and 
placed in a −80 °C freezer overnight then thawed, and 120 µL of lysis buffer (20 mM Tris-HCl,  
pH 7.5, 5 mM EDTA, 0.08% Triton X-100, 0.008% saponin with 0.2 µL/mL Sybr Green I) was 
dispensed into each well and incubated at 37 °C in the dark for 6 h. The plates were read with a 
Molecular Devices SpectraMAX Gemini EM at ex: 495 nm, em: 525 nm with 515 nm cut-off. 
3.6. MTS Dye Conversion Assay 
Compound 1 was evaluated against human colon cancer cell lines, HCT-116. In vitro cytotoxicity was 
tested with the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxylmethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt) MTS dye conversion assay as described previously [21]. 
3.7. Minimum Inhibitory Concentration for Antibacterial and Antifungal Activity  
The isolated pure compound was dissolved in MeOH at 10 mg/mL concentration and diluted further 
to give required concentrations (µg/mL) such as 500, 250, 125, 62.5, 31.25, 15.62, 7.8, 3.9, 1.9, 0.97, 
0.48, 0.24, 0.12, 0.06, 0.03 and 0.01. The diluted solutions (100 µL) were added to separate wells on a 
96 wells plate. An inoculum of 100 µL from 24 h old culture of each test human pathogens, wild type 
C. albicans ATCC 32354 and amphotericin resistant C. albicans ATCC 90873, were inoculated 
separately in each well. The antifungal agent nystatin and the solvent MeOH were included in the 
bioassay as positive and negative controls, respectively. The treated cultures were incubated for 24 h at 
37 °C. Replicates were maintained for each treatment. The MIC was defined as the lowest concentration 
of the purified compound/nystatin showing no visible growth after the incubation time. In the case of 
antibacterial assays were performed using methicillin-resistant S. aureus (MRSA, ATCC 10537) and 
vancomycin-resistant  E. faecium (VREF, ATCC 12952) as test pathogens. Vancomycin and 
chloramphenicol were used as positive controls for MRSA and VREF, respectively, and MeOH was 
used as negative control.  
4. Conclusions  
In conclusion, we described a new tetramic acid glycoside, aurantoside K (1) from a marine sponge 
Melophlus  sp. Aurantoside K (1) was evaluated in different bioassays that displayed promising 
antifungal activity against a wide spectrum of fungal pathogens. However, it showed no appreciable 
activity against human cancer cell lines, the malaria parasite P. falciparum, or any bacteria tested in 
our assays. Mar. Drugs 2012, 10                 
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